Iron Deficiency Anemia Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Powered by 
All the vital news, analysis, and commentary curated by our industry experts.
Anemia is a condition in which the body does not have enough healthy red blood cells. Iron helps make red blood cells. When the body does not have enough iron, it will make fewer red blood cells or red blood cells that are too small. This is called iron deficiency anemia. Symptoms include feeling grumpy, headaches, and problems concentrating or thinking. Treatment includes iron supplements and eating iron-rich foods.
The Iron Deficiency Anemia drugs in development market research report provide comprehensive information on the therapeutics under development for Iron Deficiency Anemia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Iron Deficiency Anemia and features dormant and discontinued projects.
Key Targets in the Iron Deficiency Anemia Pipeline Products Market
The key targets in the Iron Deficiency Anemia pipeline products market are Activin Receptor Type 1, Iron, Hemojuvelin, Ferritin, and Natural Resistance Associated Macrophage Protein 2.
Iron Deficiency Anemia Pipeline Products Analysis Market by Targets
For more target insights, download a free report sample
Key Mechanisms of Action in the Iron Deficiency Anemia Pipeline Products Market
The key mechanisms of action in the Iron Deficiency Anemia pipeline products market are Activin Receptor Type 1 Inhibitor, Iron Replacement, Hemojuvelin Inhibitor, Iron Chelator, and Natural Resistance Associated Macrophage Protein 2 Inhibitor.
Iron Deficiency Anemia Pipeline Products Market Analysis by Mechanism of Actions
For more mechanism of actions insights, download a free report sample
Key Routes of Administration in the Iron Deficiency Anemia Pipeline Products Market
The key routes of administration in the Iron Deficiency Anemia pipeline products market are intravenous, oral, and intraperitoneal.
Iron Deficiency Anemia Pipeline Products Market Analysis by Routes of Administration
For more routes of administration insights, download a free report sample
Key Molecule Types in the Iron Deficiency Anemia Pipeline Products Market
The key molecule types in the Iron Deficiency Anemia pipeline products market are small molecule, monoclonal antibody, antibody, and biologic.
Iron Deficiency Anemia Pipeline Products Market Analysis by Molecule Type
For more molecule type insights, download a free report sample
Major Companies in the Iron Deficiency Anemia Pipeline Products Market
Some of the major companies in the Iron Deficiency Anemia pipeline products market are Keros Therapeutics Inc, Rockwell Medical Inc, Disc Medicine Inc, Pharmacosmos AS, Shield Therapeutics Plc, Akebia Therapeutics Inc, Entrinsic Bioscience Inc, Iron4u Aps, Jiangsu Aosaikang Pharmaceutical Co Ltd, and Nemysis Ltd.
Iron Deficiency Anemia Pipeline Products Market Analysis by Companies
To know more about major companies, download a free report sample
Market Report Overview
| Key targets | Activin Receptor Type 1, Iron, Hemojuvelin, Ferritin, and Natural Resistance Associated Macrophage Protein 2 |
| Key mechanism of action | Activin Receptor Type 1 Inhibitor, Iron Replacement, Hemojuvelin Inhibitor, Iron Chelator, and Natural Resistance Associated Macrophage Protein 2 Inhibitor |
| Key routes of administration | Intravenous, Oral, and Intraperitoneal |
| Key molecule type | Small Molecule, Monoclonal Antibody, Antibody, and Biologic |
| Major companies | Keros Therapeutics Inc, Rockwell Medical Inc, Disc Medicine Inc, Pharmacosmos AS, Shield Therapeutics Plc, Akebia Therapeutics Inc, Entrinsic Bioscience Inc, Iron4u Aps, Jiangsu Aosaikang Pharmaceutical Co Ltd, and Nemysis Ltd |
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Iron Deficiency Anemia (Hematological Disorders).
- The pipeline guide reviews pipeline therapeutics for Iron Deficiency Anemia (Hematological Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Iron Deficiency Anemia (Hematological Disorders) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Iron Deficiency Anemia (Hematological Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA), and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews the latest news related to pipeline therapeutics for Iron Deficiency Anemia (Hematological Disorders)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Iron Deficiency Anemia (Hematological Disorders).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and their most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Iron Deficiency Anemia (Hematological Disorders) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from the pipeline.
Disc Medicine Inc
Entrinsic Bioscience Inc
Iron4u Aps
Jiangsu Aosaikang Pharmaceutical Co Ltd
Keros Therapeutics Inc
Nemysis Ltd
Novartis AG
Pharmacosmos AS
Renibus Therapeutics Inc
Rockwell Medical Inc
Shield Therapeutics Plc
Vifor Pharma Ltd
Table of Contents
Table
Figures
Frequently asked questions
-
What are the key targets in the Iron Deficiency Anemia pipeline products market?
The key targets in the Iron Deficiency Anemia pipeline products market are Activin Receptor Type 1, Iron, Hemojuvelin, Ferritin, and Natural Resistance Associated Macrophage Protein 2.
-
What are the key mechanisms of action in the Iron Deficiency Anemia pipeline products market?
The key mechanisms of action in the Iron Deficiency Anemia pipeline products market are Activin Receptor Type 1 Inhibitor, Iron Replacement, Hemojuvelin Inhibitor, Iron Chelator, and Natural Resistance Associated Macrophage Protein 2 Inhibitor.
-
What are the key routes of administration in the Iron Deficiency Anemia pipeline products market?
The key routes of administration in the Iron Deficiency Anemia pipeline products market are intravenous, oral, and intraperitoneal.
-
What are the key molecule types in the Iron Deficiency Anemia pipeline products market?
The key molecule types in the Iron Deficiency Anemia pipeline products market are small molecule, monoclonal antibody, antibody, and biologic.
-
Which are the major companies in the Iron Deficiency Anemia pipeline products market?
Some of the major companies in the Iron Deficiency Anemia pipeline products market are Keros Therapeutics Inc, Rockwell Medical Inc, Disc Medicine Inc, Pharmacosmos AS, Shield Therapeutics Plc, Akebia Therapeutics Inc, Entrinsic Bioscience Inc, Iron4u Aps, Jiangsu Aosaikang Pharmaceutical Co Ltd, and Nemysis Ltd.
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.
Related reports
View more Hematological Disorders reports